| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.536 | 0.04 | 0.586 | Analgesic | 0.586 0.029 DBMET00693 | DBMET00693 | |
| 0.444 | 0.054 | 0.452 | Calcium channel L-type activator | 0.452 0.05 DBMET00693 | DBMET00693 | |
| 0.385 | 0.03 | 0.385 | HERG channel blocker | |||
| 0.33 | 0.041 | 0.33 | Potassium channel (Voltage-sensitive) blocker | |||
| 0.28 | 0.011 | 0.28 | Nav1.3 sodium channel blocker | 0.109 0.086 DBMET00693 | ||
| 0.306 | 0.044 | 0.306 | Potassium channel blocker | |||
| 0.361 | 0.114 | 0.398 | Cyclophilin D inhibitor | 0.398 0.092 DBMET00693 | DBMET00693 | |
| 0.252 | 0.03 | 0.252 | MAP kinase kinase 3 inhibitor | 0.204 0.111 DBMET00693 | ||
| 0.245 | 0.025 | 0.245 | Cytokine production inhibitor | 0.131 0.079 DBMET00693 | ||
| 0.321 | 0.103 | 0.321 | Antiobesity | 0.278 0.133 DBMET00693 | ||
| 0.3 | 0.135 | 0.309 | Antibacterial | 0.309 0.128 DBMET00693 | DBMET00693 | |
| 0.178 | 0.017 | 0.178 | Nav1.5 sodium channel blocker | |||
| 0.216 | 0.072 | 0.216 | Anticonvulsant | 0.144 0.136 DBMET00693 | ||
| 0.146 | 0.015 | 0.406 | Vanilloid 1 antagonist | 0.406 0.005 DBMET00693 | DBMET00693 | |
| 0.228 | 0.101 | 0.228 | 5 Hydroxytryptamine release stimulant | 0.182 0.139 DBMET00693 | ||
| 0.163 | 0.046 | 0.163 | Sodium channel (voltage-gated) blocker | 0.152 0.053 DBMET00693 | ||
| 0.135 | 0.018 | 0.135 | 5 Hydroxytryptamine uptake inhibitor | |||
| 0.161 | 0.05 | 0.161 | Sodium channel blocker | 0.123 0.081 DBMET00693 | ||
| 0.149 | 0.055 | 0.149 | Nav1.6 sodium channel blocker | |||
| 0.152 | 0.058 | 0.152 | MAP kinase kinase 4 inhibitor | 0.133 0.103 DBMET00693 | ||
| 0.117 | 0.027 | 0.117 | Adrenaline agonist | |||
| 0.104 | 0.018 | 0.104 | Adrenaline uptake inhibitor | |||
| 0.094 | 0.009 | 0.123 | Heme oxygenase stimulant | 0.123 0.004 DBMET00693 | DBMET00693 | |
| 0.201 | 0.118 | 0.201 | Cardiotonic | |||
| 0.171 | 0.089 | 0.171 | P-glycoprotein inhibitor | |||
| 0.085 | 0.009 | 0.262 | Liver X receptor agonist | 0.262 0.004 DBMET00693 | DBMET00693 | |
| 0.15 | 0.082 | 0.15 | Thrombolytic | 0.133 0.096 DBMET00693 | ||
| 0.099 | 0.033 | 0.163 | Phosphodiesterase 11A inhibitor | 0.163 0.008 DBMET00693 | DBMET00693 | |
| 0.099 | 0.033 | 0.163 | Phosphodiesterase XI inhibitor | 0.163 0.008 DBMET00693 | DBMET00693 | |
| 0.121 | 0.055 | 0.171 | CDK3/cyclin E inhibitor | 0.171 0.015 DBMET00693 | DBMET00693 | |
| 0.107 | 0.042 | 0.38 | ABCA1 expression enhancer | 0.38 0.004 DBMET00693 | DBMET00693 | |
| 0.133 | 0.074 | 0.133 | Calcium channel blocker | 0.123 0.084 DBMET00693 | ||
| 0.116 | 0.061 | 0.116 | Calcium channel (voltage-sensitive) blocker | 0.111 0.068 DBMET00693 | ||
| 0.185 | 0.133 | 0.185 | Spasmolytic | |||
| 0.056 | 0.009 | 0.056 | Phenylethanolamine N methyltransferase inhibitor | |||
| 0.05 | 0.007 | 0.074 | Cholesterol ester transfer protein antagonist | 0.074 0.004 DBMET00693 | DBMET00693 | |
| 0.2 | 0.158 | 0.2 | Nootropic | |||
| 0.052 | 0.009 | 0.252 | Liver X receptor antagonist | 0.252 0.003 DBMET00693 | DBMET00693 | |
| 0.08 | 0.038 | 0.08 | Toll-Like receptor 7 antagonist | |||
| 0.048 | 0.006 | 0.236 | Liver X receptor alpha antagonist | 0.236 0.003 DBMET00693 | DBMET00693 | |
| 0.052 | 0.011 | 0.052 | Potassium channel subfamily K member 3 blocker | 0.05 0.012 DBMET00693 | ||
| 0.063 | 0.024 | 0.063 | Dopamine transporter inhibitor | |||
| 0.198 | 0.16 | 0.24 | Insulysin inhibitor | 0.24 0.106 DBMET00693 | DBMET00693 | |
| 0.053 | 0.014 | 0.053 | Estradiol 17 beta-dehydrogenase 2 inhibitor | |||
| 0.077 | 0.041 | 0.077 | Potassium channel (Tandem pore domain) blocker | 0.076 0.045 DBMET00693 | ||
| 0.101 | 0.065 | 0.101 | Nav1.1 sodium channel blocker | |||
| 0.051 | 0.023 | 0.159 | Dihydroorotase inhibitor | 0.159 0.004 DBMET00693 | DBMET00693 | |
| 0.073 | 0.053 | 0.118 | Vanilloid antagonist | 0.118 0.029 DBMET00693 | DBMET00693 | |
| 0.052 | 0.035 | 0.052 | 5 Hydroxytryptamine 2 agonist | |||
| 0.061 | 0.045 | 0.061 | Beta 2 adrenoreceptor agonist | |||
| 0.057 | 0.045 | 0.057 | Ca(v)3.2 blocker | |||
| 0.044 | 0.035 | 0.044 | Beta adrenoreceptor agonist | |||
| 0.048 | 0.041 | 0.077 | Factor IXa inhibitor | 0.077 0.017 DBMET00693 | DBMET00693 | |
| 0.021 | 0.018 | 0.127 | Bombesin agonist | 0.127 0.003 DBMET00693 | DBMET00693 | |
| 0.099 | 0.097 | 0.14 | Calcium channel N-type blocker | 0.14 0.044 DBMET00693 | DBMET00693 | |
| 0.134 | 0.132 | 0.224 | ATPase inhibitor | 0.224 0.022 DBMET00693 | DBMET00693 | |
| 0.105 | 0.103 | 0.105 | Nav1.2 sodium channel blocker | |||
| 0.017 | 0.016 | 0.106 | Bombesin 3 receptor agonist | 0.106 0.003 DBMET00693 | DBMET00693 | |
| 0.041 | 0.04 | 0.041 | Dipeptidyl peptidase IV inhibitor | |||
| 0.063 | 0.064 | 0.077 | Calcium channel L-type blocker | 0.077 0.043 DBMET00693 | DBMET00693 | |
| 0.003 | 0.013 | 0.006 | Insulin like growth factor 3 antagonist | 0.006 0.004 DBMET00693 | DBMET00693 | |
| 0.26 | 0.271 | 0.553 | Ca2+/calmodulin-dependent protein kinase kinase A inhibitor | 0.553 0.015 DBMET00693 | DBMET00693 | |
| 0.048 | 0.06 | 0.06 | Androgen agonist | 0.06 0.042 DBMET00693 | DBMET00693 | |
| 0.066 | 0.081 | 0.15 | Ca(v)2.2 blocker | 0.15 0.029 DBMET00693 | DBMET00693 | |
| 0.067 | 0.083 | 0.126 | Sphingosine 1-phosphate receptor antagonist | 0.126 0.011 DBMET00693 | DBMET00693 | |
| 0.143 | 0.166 | 0.171 | Cyclic AMP phosphodiesterase inhibitor | 0.171 0.121 DBMET00693 | DBMET00693 | |
| 0.021 | 0.046 | 0.084 | Glutamate (mGluR2) antagonist | 0.084 0.004 DBMET00693 | DBMET00693 | |
| 0.028 | 0.054 | 0.035 | Tryptophan 5 hydroxylase inhibitor | 0.035 0.028 DBMET00693 | DBMET00693 | |
| 0.031 | 0.057 | 0.041 | Vanilloid 3 antagonist | 0.041 0.019 DBMET00693 | DBMET00693 | |
| 0.026 | 0.053 | 0.109 | Glutamate (mGluR group II) antagonist | 0.109 0.004 DBMET00693 | DBMET00693 | |
| 0.01 | 0.04 | 0.018 | Kainate receptor 3 antagonist | 0.018 0.011 DBMET00693 | DBMET00693 | |
| 0.044 | 0.078 | 0.064 | Sphingosine 1-phosphate receptor 1 antagonist | 0.064 0.023 DBMET00693 | DBMET00693 | |
| 0.021 | 0.056 | 0.094 | Glutamate (mGluR group II) agonist | 0.094 0.008 DBMET00693 | DBMET00693 | |
| 0.018 | 0.056 | 0.088 | Glutamate (mGluR2) agonist | 0.088 0.008 DBMET00693 | DBMET00693 | |
| 0.014 | 0.055 | 0.159 | Liver X receptor beta antagonist | 0.159 0.003 DBMET00693 | DBMET00693 | |
| 0.011 | 0.056 | 0.024 | Kainate receptor 4 antagonist | 0.024 0.018 DBMET00693 | DBMET00693 | |
| 0.165 | 0.214 | 0.182 | Tyrosine 3 hydroxylase inhibitor | 0.182 0.172 DBMET00693 | DBMET00693 | |
| 0.049 | 0.099 | 0.171 | Nav1.8 sodium channel blocker | 0.171 0.011 DBMET00693 | DBMET00693 | |
| 0.025 | 0.076 | 0.147 | Liver X receptor alpha agonist | 0.147 0.004 DBMET00693 | DBMET00693 | |
| 0.029 | 0.081 | 0.352 | Dihydroorotate dehydrogenase inhibitor | 0.352 0.003 DBMET00693 | DBMET00693 | |
| 0.1 | 0.156 | 0.169 | Sphingosine 1-phosphate receptor 2 antagonist | 0.169 0.022 DBMET00693 | DBMET00693 | |
| 0.108 | 0.165 | 0.187 | Sphingosine 1-phosphate receptor 5 antagonist | 0.187 0.018 DBMET00693 | DBMET00693 | |
| 0.016 | 0.081 | 0.127 | Liver X receptor beta agonist | 0.127 0.004 DBMET00693 | DBMET00693 | |
| 0.008 | 0.073 | 0.025 | Kainate receptor 5 antagonist | 0.025 0.012 DBMET00693 | DBMET00693 | |
| 0.041 | 0.109 | 0.06 | Nav1.7 sodium channel blocker | 0.06 0.058 DBMET00693 | DBMET00693 | |
| 0.006 | 0.084 | 0.065 | Angiotensin AT2 receptor antagonist | 0.065 0.007 DBMET00693 | DBMET00693 | |
| 0.084 | 0.166 | 0.13 | Interleukin 2 antagonist | 0.13 0.033 DBMET00693 | DBMET00693 | |
| 0.025 | 0.109 | 0.149 | Plasminogen activator inhibitor antagonist | 0.149 0.005 DBMET00693 | DBMET00693 | |
| 0.014 | 0.102 | 0.025 | Glutamate (mGluR1) agonist | 0.025 0.015 DBMET00693 | DBMET00693 | |
| 0.028 | 0.12 | 0.049 | CC chemokine 2 receptor antagonist | 0.049 0.046 DBMET00693 | DBMET00693 | |
| 0.008 | 0.104 | 0.029 | Glutamate (mGluR1a) agonist | 0.029 0.009 DBMET00693 | DBMET00693 | |
| 0.108 | 0.206 | 0.145 | CC chemokine 6 receptor antagonist | 0.145 0.03 DBMET00693 | DBMET00693 | |
| 0.005 | 0.104 | 0.029 | Angiotensin AT1A receptor antagonist | 0.029 0.007 DBMET00693 | DBMET00693 | |
| 0.056 | 0.157 | 0.225 | GABA C receptor agonist | 0.225 0.016 DBMET00693 | DBMET00693 | |
| 0.014 | 0.116 | 0.037 | NMDA receptor subunit 3A antagonist | 0.037 0.028 DBMET00693 | DBMET00693 | |
| 0.041 | 0.143 | 0.099 | Androgen antagonist | 0.099 0.047 DBMET00693 | DBMET00693 | |
| 0.022 | 0.126 | 0.035 | Glutamate (mGluR8) antagonist | 0.035 0.026 DBMET00693 | DBMET00693 | |
| 0.004 | 0.111 | 0.02 | Kainate receptor 1 antagonist | 0.02 0.015 DBMET00693 | DBMET00693 | |
| 0.008 | 0.118 | 0.042 | Diacylglycerol O-acyltransferase 1 inhibitor | 0.042 0.012 DBMET00693 | DBMET00693 | |
| 0.124 | 0.238 | 0.263 | Superoxide dismutase inhibitor | 0.263 0.067 DBMET00693 | DBMET00693 | |
| 0.023 | 0.138 | 0.09 | Diacylglycerol O-acyltransferase inhibitor | 0.09 0.01 DBMET00693 | DBMET00693 | |
| 0.026 | 0.143 | 0.07 | Aldosterone antagonist | 0.07 0.014 DBMET00693 | DBMET00693 | |
| 0.022 | 0.14 | 0.052 | Maillard reaction inhibitor | 0.052 0.041 DBMET00693 | DBMET00693 | |
| 0.151 | 0.272 | 0.233 | Apoptosis antagonist | 0.233 0.145 DBMET00693 | DBMET00693 | |
| 0.096 | 0.218 | 0.271 | Hypolipemic | 0.271 0.059 DBMET00693 | DBMET00693 | |
| 0.129 | 0.253 | 0.255 | Transcription factor NF kappa B inhibitor | 0.255 0.124 DBMET00693 | DBMET00693 | |
| 0.036 | 0.161 | 0.105 | Histone deacetylase stimulant | 0.105 0.025 DBMET00693 | DBMET00693 | |
| 0.036 | 0.161 | 0.105 | Histone deacetylase SIRT1 stimulant | 0.105 0.025 DBMET00693 | DBMET00693 | |
| 0.016 | 0.141 | 0.049 | Phosphodiesterase 2A inhibitor | 0.049 0.035 DBMET00693 | DBMET00693 | |
| 0.044 | 0.175 | 0.094 | Potassium channel activator | 0.094 0.055 DBMET00693 | DBMET00693 | |
| 0.014 | 0.145 | 0.057 | Phosphodiesterase II inhibitor | 0.057 0.036 DBMET00693 | DBMET00693 | |
| 0.028 | 0.16 | 0.14 | Glutamate receptor agonist | 0.14 0.02 DBMET00693 | DBMET00693 | |
| 0.009 | 0.14 | 0.04 | Kainate receptor 2 antagonist | 0.04 0.022 DBMET00693 | DBMET00693 | |
| 0.028 | 0.16 | 0.066 | Syk tyrosine kinase inhibitor | 0.066 0.054 DBMET00693 | DBMET00693 | |
| 0.013 | 0.147 | 0.048 | Sphingosine 1-phosphate receptor 1 agonist | 0.048 0.021 DBMET00693 | DBMET00693 | |
| 0.024 | 0.159 | 0.085 | Glutamate (mGluR4) antagonist | 0.085 0.007 DBMET00693 | DBMET00693 | |
| 0.018 | 0.153 | 0.044 | NMDA receptor subunit 3B antagonist | 0.044 0.03 DBMET00693 | DBMET00693 | |
| 0.017 | 0.158 | 0.063 | Sphingosine 1-phosphate receptor agonist | 0.063 0.014 DBMET00693 | DBMET00693 | |
| 0.012 | 0.154 | 0.064 | Purinergic P2Y14 antagonist | 0.064 0.005 DBMET00693 | DBMET00693 | |
| 0.037 | 0.18 | 0.098 | Potassium channel large-conductance Ca-activated activator | 0.098 0.025 DBMET00693 | DBMET00693 | |
| 0.018 | 0.164 | 0.048 | AMPA 4 receptor antagonist | 0.048 0.017 DBMET00693 | DBMET00693 | |
| 0.082 | 0.233 | 0.112 | Vanilloid 1 agonist | 0.112 0.11 DBMET00693 | DBMET00693 | |
| 0.02 | 0.172 | 0.067 | Glutamate (mGluR8) agonist | 0.067 0.005 DBMET00693 | DBMET00693 | |
| 0.048 | 0.204 | 0.163 | Glutamate receptor antagonist | 0.163 0.042 DBMET00693 | DBMET00693 | |
| 0.029 | 0.193 | 0.068 | Aminopeptidase I inhibitor | 0.068 0.055 DBMET00693 | DBMET00693 | |
| 0.004 | 0.168 | 0.035 | AMPA 1 receptor antagonist | 0.035 0.017 DBMET00693 | DBMET00693 | |
| 0.002 | 0.168 | 0.025 | Angiotensin AT1B receptor antagonist | 0.025 0.005 DBMET00693 | DBMET00693 | |
| 0.013 | 0.179 | 0.069 | Angiotensin II receptor antagonist | 0.069 0.004 DBMET00693 | DBMET00693 | |
| 0.007 | 0.174 | 0.027 | AMPA 3 receptor antagonist | 0.027 0.023 DBMET00693 | DBMET00693 | |
| 0.109 | 0.277 | 0.17 | Ca2+-transporting ATPase inhibitor | 0.17 0.013 DBMET00693 | DBMET00693 | |
| 0.017 | 0.188 | 0.076 | Glutamate (mGluR) agonist | 0.076 0.033 DBMET00693 | DBMET00693 | |
| 0.041 | 0.212 | 0.206 | Creatine kinase inhibitor | 0.206 0.01 DBMET00693 | DBMET00693 | |
| 0.003 | 0.175 | 0.035 | Egl nine homolog 3 inhibitor | 0.035 0.003 DBMET00693 | DBMET00693 | |
| 0.007 | 0.181 | 0.049 | Kainate receptor antagonist | 0.049 0.022 DBMET00693 | DBMET00693 | |
| 0.012 | 0.186 | 0.068 | Angiotensin AT1 receptor antagonist | 0.068 0.004 DBMET00693 | DBMET00693 | |
| 0.031 | 0.209 | 0.082 | Aryl hydrocarbon receptor antagonist | 0.082 0.025 DBMET00693 | DBMET00693 | |
| 0.007 | 0.186 | 0.031 | Prostaglandin EP4 antagonist | 0.031 0.015 DBMET00693 | DBMET00693 | |
| 0.007 | 0.188 | 0.089 | Urate transporter 1 inhibitor | 0.089 0.006 DBMET00693 | DBMET00693 | |
| 0.003 | 0.189 | 0.016 | Thrombopoietin agonist | 0.016 0.005 DBMET00693 | DBMET00693 | |
| 0.022 | 0.209 | 0.109 | Phenylalanine 4-hydroxylase inhibitor | 0.109 0.022 DBMET00693 | DBMET00693 | |
| 0.012 | 0.201 | 0.036 | GABA uptake inhibitor | 0.036 0.033 DBMET00693 | DBMET00693 | |
| 0.023 | 0.213 | 0.08 | Glutamate (mGluR group III) antagonist | 0.08 0.007 DBMET00693 | DBMET00693 | |
| 0.026 | 0.229 | 0.082 | Dihydroorotate oxidase inhibitor | 0.082 0.009 DBMET00693 | DBMET00693 | |
| 0.029 | 0.232 | 0.167 | Potassium channel (Ca-activated) activator | 0.167 0.023 DBMET00693 | DBMET00693 | |
| 0.107 | 0.312 | 0.168 | Heat shock protein 70 antagonist | 0.168 0.019 DBMET00693 | DBMET00693 | |
| 0.043 | 0.251 | 0.081 | MDM2 inhibitor | 0.081 0.019 DBMET00693 | DBMET00693 | |
| 0.019 | 0.229 | 0.149 | Aconitate hydratase inhibitor | 0.149 0.004 DBMET00693 | DBMET00693 | |
| 0.02 | 0.233 | 0.058 | Sphingosine 1-phosphate receptor 3 antagonist | 0.058 0.042 DBMET00693 | DBMET00693 | |
| 0.136 | 0.35 | 0.224 | 5 Hydroxytryptamine uptake stimulant | 0.224 0.112 DBMET00693 | DBMET00693 | |
| 0.059 | 0.28 | 0.145 | Cell wall synthesis inhibitor | 0.145 0.071 DBMET00693 | DBMET00693 | |
| 0.03 | 0.252 | 0.077 | Ornithine decarboxylase inhibitor | 0.077 0.071 DBMET00693 | DBMET00693 | |
| 0.004 | 0.226 | 0.024 | NMDA receptor glycine site antagonist | 0.024 0.017 DBMET00693 | DBMET00693 | |
| 0.045 | 0.269 | 0.276 | Alpha-N-acetylglucosaminidase inhibitor | 0.276 0.019 DBMET00693 | DBMET00693 | |
| 0.039 | 0.267 | 0.117 | GABA C receptor antagonist | 0.117 0.055 DBMET00693 | DBMET00693 | |
| 0.036 | 0.27 | 0.116 | Potassium channel (Voltage-sensitive) activator | 0.116 0.036 DBMET00693 | DBMET00693 | |
| 0.058 | 0.292 | 0.159 | Protein kinase (CK1) gamma 3 inhibitor | 0.159 0.08 DBMET00693 | DBMET00693 | |
| 0.013 | 0.248 | 0.059 | Nerve growth factor antagonist | 0.059 0.01 DBMET00693 | DBMET00693 | |
| 0.007 | 0.248 | 0.024 | Retinoic acid beta receptor agonist | 0.024 0.009 DBMET00693 | DBMET00693 | |
| 0.005 | 0.247 | 0.04 | Peroxisome proliferator-activated receptor delta agonist | 0.04 0.017 DBMET00693 | DBMET00693 | |
| 0.111 | 0.359 | 0.277 | Toll-Like receptor 7 agonist | 0.277 0.126 DBMET00693 | DBMET00693 | |
| 0.012 | 0.264 | 0.062 | Retinoic acid alpha receptor agonist | 0.062 0.008 DBMET00693 | DBMET00693 | |
| 0.092 | 0.345 | 0.141 | Catenin beta inhibitor | 0.141 0.129 DBMET00693 | DBMET00693 | |
| 0.033 | 0.287 | 0.078 | Glutamate (mGluR6) antagonist | 0.078 0.026 DBMET00693 | DBMET00693 | |
| 0.107 | 0.366 | 0.268 | Toll-Like receptor agonist | 0.268 0.133 DBMET00693 | DBMET00693 | |
| 0.002 | 0.261 | 0.02 | Egl nine homolog 1 inhibitor | 0.02 0.005 DBMET00693 | DBMET00693 | |
| 0.007 | 0.271 | 0.035 | Nicotinic acid receptor 2 agonist | 0.035 0.025 DBMET00693 | DBMET00693 | |
| 0.013 | 0.277 | 0.099 | TRPA1 antagonist | 0.099 0.018 DBMET00693 | DBMET00693 | |
| 0.004 | 0.27 | 0.023 | Retinoid X beta receptor agonist | 0.023 0.013 DBMET00693 | DBMET00693 | |
| 0.028 | 0.296 | 0.095 | Aminopeptidase B inhibitor | 0.095 0.069 DBMET00693 | DBMET00693 | |
| 0.033 | 0.302 | 0.114 | HIV-1 integrase (Overall Integration) inhibitor | 0.114 0.043 DBMET00693 | DBMET00693 | |
| 0.009 | 0.28 | 0.04 | Glutamate (mGluR3) antagonist | 0.04 0.02 DBMET00693 | DBMET00693 | |
| 0.005 | 0.277 | 0.031 | Free fatty acid receptor 1 antagonist | 0.031 0.028 DBMET00693 | DBMET00693 | |
| 0.056 | 0.329 | 0.131 | Sphingosine 1-phosphate receptor 4 antagonist | 0.131 0.055 DBMET00693 | DBMET00693 | |
| 0.093 | 0.37 | 0.192 | Neuropeptide Y2 antagonist | 0.192 0.135 DBMET00693 | DBMET00693 | |
| 0.03 | 0.308 | 0.066 | Exportin-1 inhibitor | 0.066 0.054 DBMET00693 | DBMET00693 | |
| 0.005 | 0.284 | 0.071 | AMPA receptor antagonist | 0.071 0.02 DBMET00693 | DBMET00693 | |
| 0.007 | 0.287 | 0.046 | Nicotinic acid receptor agonist | 0.046 0.016 DBMET00693 | DBMET00693 | |
| 0.035 | 0.319 | 0.099 | GABA C receptor rho-1 antagonist | 0.099 0.064 DBMET00693 | DBMET00693 | |
| 0.005 | 0.29 | 0.098 | TRPM8 blocker | 0.098 0.007 DBMET00693 | DBMET00693 | |
| 0.033 | 0.319 | 0.217 | Cyclooxygenase 2 inhibitor | 0.217 0.026 DBMET00693 | DBMET00693 | |
| 0.044 | 0.332 | 0.12 | Aldehyde dehydrogenase inhibitor | 0.12 0.07 DBMET00693 | DBMET00693 | |
| 0.035 | 0.324 | 0.15 | Triose-phosphate isomerase inhibitor | 0.15 0.02 DBMET00693 | DBMET00693 | |
| 0.006 | 0.299 | 0.024 | Lysophosphatidic acid 1 receptor antagonist | 0.024 0.01 DBMET00693 | DBMET00693 | |
| 0.037 | 0.33 | 0.133 | Electrolyte absorption antagonist | 0.133 0.028 DBMET00693 | DBMET00693 | |
| 0.061 | 0.358 | 0.272 | Non-steroidal antiinflammatory agent | 0.272 0.035 DBMET00693 | DBMET00693 | |
| 0.007 | 0.305 | 0.022 | Retinoic acid gamma receptor agonist | 0.022 0.016 DBMET00693 | DBMET00693 | |
| 0.108 | 0.406 | 0.282 | Calcium channel activator | 0.282 0.11 DBMET00693 | DBMET00693 | |
| 0.038 | 0.341 | 0.237 | Cyclooxygenase inhibitor | 0.237 0.029 DBMET00693 | DBMET00693 | |
| 0.021 | 0.328 | 0.068 | Pregnane X receptor antagonist | 0.068 0.017 DBMET00693 | DBMET00693 | |
| 0.006 | 0.314 | 0.093 | Peroxisome proliferator-activated receptor alpha agonist | 0.093 0.014 DBMET00693 | DBMET00693 | |
| 0.062 | 0.372 | 0.124 | Pregnane X receptor agonist | 0.124 0.118 DBMET00693 | DBMET00693 | |
| 0.01 | 0.321 | 0.054 | Argininosuccinate synthase inhibitor | 0.054 0.042 DBMET00693 | DBMET00693 | |
| 0.008 | 0.319 | 0.038 | Peroxisome proliferator-activated receptor delta antagonist | 0.038 0.017 DBMET00693 | DBMET00693 | |
| 0.01 | 0.322 | 0.101 | Peroxisome proliferator-activated receptor gamma agonist | 0.101 0.027 DBMET00693 | DBMET00693 | |
| 0.004 | 0.326 | 0.023 | Retinoid X gamma receptor agonist | 0.023 0.016 DBMET00693 | DBMET00693 | |
| 0.013 | 0.337 | 0.055 | Nicotinic acid receptor 1 agonist | 0.055 0.018 DBMET00693 | DBMET00693 | |
| 0.028 | 0.354 | 0.109 | Dual specificity tyrosine-phosphorylation regulated kinase 2 inhibitor | 0.109 0.031 DBMET00693 | DBMET00693 | |
| 0.019 | 0.345 | 0.072 | Prostaglandin F2 alpha antagonist | 0.072 0.03 DBMET00693 | DBMET00693 | |
| 0.004 | 0.334 | 0.07 | Farnesoid X receptor agonist | 0.07 0.007 DBMET00693 | DBMET00693 | |
| 0.054 | 0.384 | 0.149 | Insulin secretagoues | 0.149 0.076 DBMET00693 | DBMET00693 | |
| 0.045 | 0.375 | 0.171 | Adenylate kinase inhibitor | 0.171 0.02 DBMET00693 | DBMET00693 | |
| 0.038 | 0.37 | 0.134 | Diuretic | 0.134 0.091 DBMET00693 | DBMET00693 | |
| 0.027 | 0.361 | 0.074 | Glycine receptor agonist | 0.074 0.047 DBMET00693 | DBMET00693 | |
| 0.014 | 0.352 | 0.04 | Glutamate (mGluR group III) agonist | 0.04 0.034 DBMET00693 | DBMET00693 | |
| 0.009 | 0.348 | 0.062 | NMDA receptor glycine site agonist | 0.062 0.044 DBMET00693 | DBMET00693 | |
| 0.006 | 0.345 | 0.062 | Retinoid X alpha receptor agonist | 0.062 0.01 DBMET00693 | DBMET00693 | |
| 0.126 | 0.465 | 0.334 | Antiinflammatory | 0.334 0.185 DBMET00693 | DBMET00693 | |
| 0.019 | 0.366 | 0.075 | Glutamate (mGluR7) antagonist | 0.075 0.034 DBMET00693 | DBMET00693 | |
| 0.012 | 0.36 | 0.05 | Thromboxane synthase inhibitor | 0.05 0.049 DBMET00693 | DBMET00693 | |
| 0.013 | 0.362 | 0.092 | Glutamate decarboxylase inhibitor | 0.092 0.035 DBMET00693 | DBMET00693 | |
| 0.044 | 0.395 | 0.116 | Interleukin 4 antagonist | 0.116 0.091 DBMET00693 | DBMET00693 | |
| 0.061 | 0.413 | 0.18 | Neurotrophic factor enhancer | 0.18 0.098 DBMET00693 | DBMET00693 | |
| 0.013 | 0.365 | 0.198 | Porphobilinogen synthase inhibitor | 0.198 0.012 DBMET00693 | DBMET00693 | |
| 0.005 | 0.358 | 0.056 | Purinergic P2Y antagonist | 0.056 0.022 DBMET00693 | DBMET00693 | |
| 0.007 | 0.362 | 0.042 | Factor XIa inhibitor | 0.042 0.027 DBMET00693 | DBMET00693 | |
| 0.025 | 0.382 | 0.123 | UDP-glucose 4-epimerase inhibitor | 0.123 0.041 DBMET00693 | DBMET00693 | |
| 0.004 | 0.362 | 0.051 | Oleamide hydrolase inhibitor | 0.051 0.026 DBMET00693 | DBMET00693 | |
| 0.017 | 0.376 | 0.06 | Potassium channel intermediate-conductance Ca-activated blocker | 0.06 0.041 DBMET00693 | DBMET00693 | |
| 0.014 | 0.387 | 0.065 | 3-Hydroxyanthranilate 3,4-dioxygenase inhibitor | 0.065 0.005 DBMET00693 | DBMET00693 | |
| 0.023 | 0.397 | 0.242 | Ferrochelatase inhibitor | 0.242 0.014 DBMET00693 | DBMET00693 | |
| 0.006 | 0.381 | 0.041 | Thymidylate synthase inhibitor | 0.041 0.04 DBMET00693 | DBMET00693 | |
| 0.027 | 0.402 | 0.071 | GABA B receptor agonist | 0.071 0.065 DBMET00693 | DBMET00693 | |
| 0.005 | 0.38 | 0.027 | Protocollagen prolyl hydroxylase inhibitor | 0.027 0.02 DBMET00693 | DBMET00693 | |
| 0.025 | 0.404 | 0.159 | Uric acid excretion stimulant | 0.159 0.02 DBMET00693 | DBMET00693 | |
| 0.004 | 0.385 | 0.031 | Nicotinic acid receptor 2 antagonist | 0.031 0.012 DBMET00693 | DBMET00693 | |
| 0.029 | 0.414 | 0.126 | UDP-N-acetylglucosamine 1-carboxyvinyltransferase inhibitor | 0.126 0.036 DBMET00693 | DBMET00693 | |
| 0.005 | 0.39 | 0.025 | Retinoic acid receptor agonist | 0.025 0.013 DBMET00693 | DBMET00693 | |
| 0.025 | 0.412 | 0.059 | Adenine nucleotide translocase inhibitor | 0.059 0.03 DBMET00693 | DBMET00693 | |
| 0.02 | 0.409 | 0.118 | Peroxisome proliferator-activated receptor gamma antagonist | 0.118 0.01 DBMET00693 | DBMET00693 | |
| 0.001 | 0.391 | 0.024 | Peroxisome proliferator-activated receptor alpha antagonist | 0.024 0.014 DBMET00693 | DBMET00693 | |
| 0.033 | 0.423 | 0.136 | DOPA decarboxylase inhibitor | 0.136 0.03 DBMET00693 | DBMET00693 | |
| 0.075 | 0.466 | 0.441 | Histamine release inhibitor | 0.441 0.055 DBMET00693 | DBMET00693 | |
| 0.009 | 0.403 | 0.052 | Lysophosphatidic acid 3 receptor antagonist | 0.052 0.032 DBMET00693 | DBMET00693 | |
| 0.024 | 0.419 | 0.112 | AMP-activated protein kinase stimulant | 0.112 0.057 DBMET00693 | DBMET00693 | |
| 0.008 | 0.403 | 0.088 | Alcohol oxidase inhibitor | 0.088 0.021 DBMET00693 | DBMET00693 | |
| 0.009 | 0.405 | 0.031 | Glutamate (mGluR4) agonist | 0.031 0.03 DBMET00693 | DBMET00693 | |
| 0.018 | 0.416 | 0.109 | Cholesterol synthesis inhibitor | 0.109 0.077 DBMET00693 | DBMET00693 | |
| 0.053 | 0.45 | 0.143 | Interferon gamma antagonist | 0.143 0.087 DBMET00693 | DBMET00693 | |
| 0.03 | 0.429 | 0.114 | NADH dehydrogenase inhibitor | 0.114 0.032 DBMET00693 | DBMET00693 | |
| 0.003 | 0.403 | 0.05 | Retinoid X receptor agonist | 0.05 0.018 DBMET00693 | DBMET00693 | |
| 0.005 | 0.404 | 0.02 | Retinoid X beta receptor antagonist | 0.02 0.018 DBMET00693 | DBMET00693 | |
| 0.034 | 0.436 | 0.2 | Carbonic anhydrase XV inhibitor | 0.2 0.018 DBMET00693 | DBMET00693 | |
| 0.009 | 0.412 | 0.096 | Biliverdin reductase inhibitor | 0.096 0.02 DBMET00693 | DBMET00693 | |
| 0.013 | 0.418 | 0.039 | Leukotriene C4 antagonist | 0.039 0.028 DBMET00693 | DBMET00693 | |
| 0.019 | 0.435 | 0.059 | Leukotriene C antagonist | 0.059 0.031 DBMET00693 | DBMET00693 | |
| 0.003 | 0.421 | 0.032 | Prostaglandin EP1 antagonist | 0.032 0.009 DBMET00693 | DBMET00693 | |
| 0.032 | 0.45 | 0.138 | Arachidonic acid antagonist | 0.138 0.102 DBMET00693 | DBMET00693 | |
| 0.022 | 0.443 | 0.088 | Anabolic | 0.088 0.082 DBMET00693 | DBMET00693 | |
| 0.06 | 0.484 | 0.323 | Cholesterol antagonist | 0.323 0.077 DBMET00693 | DBMET00693 | |
| 0.009 | 0.436 | 0.091 | Catalase inhibitor | 0.091 0.042 DBMET00693 | DBMET00693 | |
| 0.015 | 0.443 | 0.038 | CF transmembrane conductance regulator antagonist | 0.038 0.032 DBMET00693 | DBMET00693 | |
| 0.053 | 0.486 | 0.164 | Histone acetyltransferase inhibitor | 0.164 0.121 DBMET00693 | DBMET00693 | |
| 0.014 | 0.447 | 0.042 | Guanylate cyclase stimulant | 0.042 0.034 DBMET00693 | DBMET00693 | |
| 0.01 | 0.444 | 0.033 | Retinoid X alpha receptor antagonist | 0.033 0.025 DBMET00693 | DBMET00693 | |
| 0.007 | 0.444 | 0.071 | Phosphofructokinase-1 inhibitor | 0.071 0.047 DBMET00693 | DBMET00693 | |
| 0.02 | 0.458 | 0.083 | Glutamate dehydrogenase inhibitor | 0.083 0.042 DBMET00693 | DBMET00693 | |
| 0.044 | 0.486 | 0.235 | 3C-like protease (Human coronavirus) inhibitor | 0.235 0.034 DBMET00693 | DBMET00693 | |
| 0.005 | 0.448 | 0.08 | Prostaglandin antagonist | 0.08 0.023 DBMET00693 | DBMET00693 | |
| 0.01 | 0.455 | 0.07 | Histidine decarboxylase inhibitor | 0.07 0.051 DBMET00693 | DBMET00693 | |
| 0.019 | 0.468 | 0.077 | Factor III inhibitor | 0.077 0.008 DBMET00693 | DBMET00693 | |
| 0.01 | 0.46 | 0.037 | Retinoid X receptor antagonist | 0.037 0.028 DBMET00693 | DBMET00693 | |
| 0.004 | 0.457 | 0.036 | DNA gyrase subunit B inhibitor | 0.036 0.03 DBMET00693 | DBMET00693 | |
| 0.009 | 0.464 | 0.042 | Neuraminidase (Influenza A) inhibitor | 0.042 0.038 DBMET00693 | DBMET00693 | |
| 0.017 | 0.472 | 0.094 | Purinergic P2X1 antagonist | 0.094 0.019 DBMET00693 | DBMET00693 | |
| 0.024 | 0.481 | 0.178 | Phospholipase A2 inhibitor | 0.178 0.055 DBMET00693 | DBMET00693 | |
| 0.003 | 0.462 | 0.032 | Kynurenine 3 monooxygenase inhibitor | 0.032 0.014 DBMET00693 | DBMET00693 | |
| 0.041 | 0.505 | 0.088 | Glutamate release inhibitor | 0.088 0.067 DBMET00693 | DBMET00693 | |
| 0.045 | 0.511 | 0.132 | CF transmembrane conductance regulator agonist | 0.132 0.113 DBMET00693 | DBMET00693 | |
| 0.02 | 0.487 | 0.14 | MAP kinase kinase 2 inhibitor | 0.14 0.13 DBMET00693 | DBMET00693 | |
| 0.026 | 0.499 | 0.223 | Insulin sensitizer | 0.223 0.052 DBMET00693 | DBMET00693 | |
| 0.006 | 0.481 | 0.056 | Acyl-CoA dehydrogenase inhibitor | 0.056 0.036 DBMET00693 | DBMET00693 | |
| 0.032 | 0.509 | 0.233 | Aldehyde oxidase inhibitor | 0.233 0.089 DBMET00693 | DBMET00693 | |
| 0.005 | 0.484 | 0.117 | Prostaglandin-E synthase inhibitor | 0.117 0.02 DBMET00693 | DBMET00693 | |
| 0.019 | 0.499 | 0.074 | Keratolytic | 0.074 0.057 DBMET00693 | DBMET00693 | |
| 0.005 | 0.491 | 0.1 | Prostaglandin E2 antagonist | 0.1 0.014 DBMET00693 | DBMET00693 | |
| 0.045 | 0.537 | 0.204 | Transcription factor STAT inhibitor | 0.204 0.133 DBMET00693 | DBMET00693 | |
| 0.029 | 0.521 | 0.111 | Photosensitizer | 0.111 0.069 DBMET00693 | DBMET00693 | |
| 0.056 | 0.555 | 0.151 | Lipocortins synthesis antagonist | 0.151 0.103 DBMET00693 | DBMET00693 | |
| 0.003 | 0.502 | 0.02 | Retinoic acid alpha receptor antagonist | 0.02 0.015 DBMET00693 | DBMET00693 | |
| 0.009 | 0.51 | 0.057 | DNA gyrase inhibitor | 0.057 0.053 DBMET00693 | DBMET00693 | |
| 0.025 | 0.544 | 0.14 | TRPA1 agonist | 0.14 0.038 DBMET00693 | DBMET00693 | |
| 0.028 | 0.555 | 0.198 | Succinate dehydrogenase inhibitor | 0.198 0.051 DBMET00693 | DBMET00693 | |
| 0.034 | 0.562 | 0.182 | Transcription factor STAT3 inhibitor | 0.182 0.162 DBMET00693 | DBMET00693 | |
| 0.011 | 0.539 | 0.07 | GABA aminotransferase inhibitor | 0.07 0.061 DBMET00693 | DBMET00693 | |
| 0.01 | 0.542 | 0.137 | Alcohol dehydrogenase inhibitor | 0.137 0.025 DBMET00693 | DBMET00693 | |
| 0.004 | 0.537 | 0.061 | Leukotriene antagonist | 0.061 0.05 DBMET00693 | DBMET00693 | |
| 0.005 | 0.552 | 0.078 | Xanthine dehydrogenase inhibitor | 0.078 0.026 DBMET00693 | DBMET00693 | |
| 0.035 | 0.584 | 0.19 | Ca2+/calmodulin-dependent protein kinase kinase B inhibitor | 0.19 0.024 DBMET00693 | DBMET00693 | |
| 0.005 | 0.555 | 0.085 | Protein kinase (CK2) inhibitor | 0.085 0.077 DBMET00693 | DBMET00693 | |
| 0.014 | 0.576 | 0.131 | Alkaline phosphatase inhibitor | 0.131 0.075 DBMET00693 | DBMET00693 | |
| 0.055 | 0.618 | 0.234 | GABA C receptor rho-3 antagonist | 0.234 0.169 DBMET00693 | DBMET00693 | |
| 0.012 | 0.577 | 0.155 | Cyclooxygenase 1 inhibitor | 0.155 0.054 DBMET00693 | DBMET00693 | |
| 0.004 | 0.57 | 0.11 | Protein kinase (CK2) alpha inhibitor | 0.11 0.069 DBMET00693 | DBMET00693 | |
| 0.003 | 0.569 | 0.017 | Retinoic acid receptor antagonist | 0.017 0.015 DBMET00693 | DBMET00693 | |
| 0.016 | 0.586 | 0.144 | I kappa B kinase epsilon inhibitor | 0.144 0.126 DBMET00693 | DBMET00693 | |
| 0.062 | 0.639 | 0.414 | 5 Hydroxytryptamine release inhibitor | 0.414 0.07 DBMET00693 | DBMET00693 | |
| 0.031 | 0.61 | 0.207 | Glyceraldehyde-3-phosphate dehydrogenase inhibitor | 0.207 0.067 DBMET00693 | DBMET00693 | |
| 0.026 | 0.611 | 0.08 | D-Ala-D-Ala ligase inhibitor | 0.08 0.068 DBMET00693 | DBMET00693 | |
| 0.012 | 0.596 | 0.103 | Cystathionine beta-synthase inhibitor | 0.103 0.074 DBMET00693 | DBMET00693 | |
| 0.015 | 0.604 | 0.148 | Heat shock protein 90 alpha antagonist | 0.148 0.089 DBMET00693 | DBMET00693 | |
| 0.019 | 0.614 | 0.1 | Carbonic anhydrase III inhibitor | 0.1 0.061 DBMET00693 | DBMET00693 | |
| 0.02 | 0.618 | 0.197 | Amyloid beta precursor protein antagonist | 0.197 0.06 DBMET00693 | DBMET00693 | |
| 0.005 | 0.611 | 0.056 | HIV-1 integrase (3'-Processing) inhibitor | 0.056 0.051 DBMET00693 | DBMET00693 | |
| 0.01 | 0.621 | 0.153 | Aryl hydrocarbon receptor agonist | 0.153 0.133 DBMET00693 | DBMET00693 | |
| 0.008 | 0.646 | 0.144 | Protein-tyrosine phosphatase inhibitor | 0.144 0.085 DBMET00693 | DBMET00693 | |
| 0.027 | 0.668 | 0.18 | Hexokinase inhibitor | 0.18 0.049 DBMET00693 | DBMET00693 | |
| 0.014 | 0.656 | 0.1 | Xanthine oxidase inhibitor | 0.1 0.059 DBMET00693 | DBMET00693 | |
| 0.013 | 0.704 | 0.238 | Streptokinase A inhibitor | 0.238 0.111 DBMET00693 | DBMET00693 | |
| 0.01 | 0.704 | 0.115 | Mannose-6-phosphate isomerase inhibitor | 0.115 0.11 DBMET00693 | DBMET00693 | |
| 0.005 | 0.8 | 0.162 | Mcl-1 antagonist | 0.162 0.079 DBMET00693 | DBMET00693 | |
| 0.008 | 0.846 | 0.129 | Dual specificity phosphatase inhibitor | 0.129 0.122 DBMET00693 | DBMET00693 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |